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Long-term management of hepatic encephalopathy
with lactulose and/or rifaximin: a review of the
evidence
Mark Hudsona,b and Marcus Schuchmannc
A consolidated overview of evidence for the effectiveness and safety/tolerability of hepatic encephalopathy (HE) treatment over
the long term is currently lacking. We identified and assessed published evidence for the long-term (≥6 months) pharmacological
management of HE with lactulose and/or rifaximin. A literature search was conducted in PubMed (cutoff date 05 March 2018)
using the search terms ‘hepatic encephalopathy+ rifaximin’ and ‘hepatic encephalopathy+ lactulose’. All articles containing
primary clinical data were manually assessed to identify studies in which long-term (≥6 months) effectiveness and/or safety/
tolerability end points were reported for lactulose and/or rifaximin. Long-term effectiveness outcomes were reported in eight
articles for treatment with lactulose alone and 19 articles for treatment with rifaximin, alone or in combination with lactulose. Long-
term safety/tolerability outcomes were reported in six articles for treatment with lactulose alone and nine articles for treatment with
rifaximin, alone or in combination with lactulose. These studies showed that lactulose is effective for the prevention of overt HE
recurrence over the long term and that the addition of rifaximin to lactulose significantly reduces the risk of overt HE recurrence
and HE-related hospitalization, compared with lactulose therapy alone, without compromising tolerability. Current evidence
therefore supports recommendations for the use of lactulose therapy for the prevention of overt HE recurrence over the long
term, and for the additional benefit of adding rifaximin to lactulose therapy. Addition of rifaximin to standard lactulose therapy may
result in substantial reductions in healthcare resource utilization over the long term, by reducing overt HE recurrence and
associated rehospitalization. Eur J Gastroenterol Hepatol 31:434–450
Copyright © 2018 The Author(s). Published by Wolters Kluwer Health, Inc.
Introduction
Hepatic encephalopathy (HE) is a brain dysfunction caused
by liver insufficiency and/or portosystemic shunting, which
manifests as a wide spectrum of neurological or psychiatric
abnormalities, ranging from subclinical alterations to coma
[1]. The primary pathophysiological mechanism underlying
HE is thought to involve elevated blood levels of gut-derived
neurotoxins – in particular, ammonia – entering the brain
owing to the inability of the cirrhotic liver to remove them
from the blood circulation [2–4]. HE increases the risk of
mortality [5] and is one of the most debilitating complications
of liver disease [1]. Overt HE (OHE) occurs in 30–40% of
patients with cirrhosis at some time during their clinical
course, with minimal HE (MHE) reported to potentially
affect 20–80% of patients with cirrhosis [1].
HE has a substantial economic effect, not only owing to
the direct costs of its management (particularly HE-related
hospitalization) but also to the indirect costs arising from,
for example, absence from work and loss of work pro-
ductivity [1,6,7]. HE negatively affects the lives of both
patients and caregivers [1,8] and the socioeconomic impli-
cations of HE over the longer term may be very profound,
decreasing work performance, increasing the risk of vehicle
accidents and severely impairing quality of life [1]. Currently
available treatment options for HE include nonabsorbable
disaccharides (e.g. lactulose), antibiotics (e.g. rifaximin-α
550mg) and L-ornithine L-aspartate (LOLA) [1]. Other
potential therapies include branched-chain amino acids,
probiotics, metabolic ammonia scavengers and glutaminase
inhibitors [1].
Nonabsorbable disaccharides not only remove nitrogen-
containing substances from the gastrointestinal tract via
their laxative effects but are also metabolized by the colonic
microbiota to produce short-chain organic acids [2]. These
acids are thought to inhibit the growth of ammonia-
producing bacteria and to convert ammonia to nonabsorb-
able ammonium, thereby further decreasing the ammonia
load [2]. Adherence to lactulose may be affected by its
adverse effects, which can include severe diarrhea, hypoka-
lemia, hyponatremia, bloating, flatulence, nausea and
vomiting [9,10].
The most commonly used antibiotic, rifaximin-α 550mg,
is a locally acting oral antibiotic that is minimally absorbed
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in the gut to reduce the effects of intestinal flora, including
ammonia-producing species [11,12]. Rifaximin-α 550mg is
indicated for the reduction in recurrence of episodes of
OHE in patients aged ≥18 years [13]. C. difficile-associated
diarrhea has been reported with the use of nearly all anti-
bacterial agents, including rifaximin-α 550mg [13].
Current guidelines recommend that an episode of OHE
(whether spontaneous or precipitated) should be actively
treated, and that secondary prophylaxis should be initiated
after an episode to prevent recurrence [1]. Lactulose is
recommended as the first choice for treatment of episodic
HE, and for the prevention of recurrent episodes of HE
after the initial episode [1]. Rifaximin is recommended as
an effective add-on to lactulose for the prevention of OHE
recurrence after the second episode [1]. Intravenous LOLA
and oral branched-chain amino acids can be used as
alternative or additional agents to treat patients who are
not responsive to conventional therapy [1]. Prophylactic
therapy should be continued, unless precipitating factors
(e.g. infections and variceal bleeding) have been well
controlled or liver function or nutritional status improved
[1]. However, a consolidated overview of current evidence
for the effectiveness and safety/tolerability of HE treatment
in the long-term setting is currently lacking. The aims
of this systematic review were therefore to identify and
assess published evidence for the long-term (≥6 months)
pharmacological management of HE and to discuss
the implications of this evidence for everyday clinical
practice.
Materials and methods
Literature searches were conducted in PubMed of titles
and abstracts only, with language restricted to English
and the date range unrestricted up to the cutoff date
(5 March 2018), using the following search terms: ‘hepatic
encephalopathy + rifaximin’ and ‘hepatic encephalopathy-
+ lactulose’. The abstracts of all identified articles were
manually assessed to identify primary clinical data-
containing manuscripts (i.e. articles containing clinical
trial, clinical practice study, observational, registry, health
economic and/or survey data, including journal-published
congress abstracts if indexed on PubMed). These were
then assessed to identify studies in which long-term effec-
tiveness and/or safety/tolerability end points were reported
for lactulose and/or rifaximin. Long-term treatment was
defined as at least 6 months. The results of studies were
then tabulated for further evaluation.
Similar initial searches were additionally conducted
using the search terms ‘hepatic encephalopathy+ L-ornithine-
L-aspartate, ‘hepatic encephalopathy+LOLA’ and ‘hepatic
encephalopathy+ornithine aspartate’. However, as only one
study was identified that reported long-term (≥6 months)
outcomes [14], the subsequent review process was restricted
to evidence for lactulose and rifaximin only.
Number needed to treat (NNT) analyses were carried
out for studies reporting significant between-group differ-
ences in the rate of OHE recurrence following at least
6 months of secondary prophylaxis with lactulose and/or
rifaximin. Studies investigating primary prophylaxis and
different dosing regimens of rifaximin were excluded from
the NNT analysis.
Results
The search term ‘hepatic encephalopathy + rifaximin’
identified a total of 235 articles, of which 71 were assessed
as containing primary clinical data (Fig. 1). The search
term ‘hepatic encephalopathy + lactulose’ identified 355
articles, of which 130 contained primary clinical data
(Fig. 1).
Effectiveness of long-term ( >_ 6 months) treatment of
hepatic encephalopathy with rifaximin and/or lactulose
Manual assessment of the articles containing primary clinical
data identified long-term effectiveness outcomes for treatment
of HE, with eight articles reporting outcomes for treatment
with lactulose alone and a further 19 articles reporting out-
comes for treatment with rifaximin, alone or in combination
with lactulose (Table 1). NNT analyses were carried out of
studies reporting at least 6 months of secondary prophylaxis
with lactulose versus no lactulose (n=1) [34], lactulose versus
placebo (n=1) [38], rifaximin+ lactulose versus placebo-
+ lactulose (n=2) [16,19] and rifaximin monotherapy versus
rifaximin+ lactulose (n=1) [31] (Fig. 2). Details of studies
including more than 100 patients are summarized in more
detail later.
Lactulose alone
In a single-center, retrospective, chart review of 137
patients who received lactulose for a mean duration of
27 ±6 months after their first HE event, it was found that
75% of the patients experienced HE recurrence after
9 ±1 months [10]. The rate of HE-related hospital read-
mission was 73%, and the mortality rate was 34% [10].
Thirty-nine (28.5%) patients had HE recurrence asso-
ciated with lactulose nonadherence, mostly resulting from
gastrointestinal adverse effects [10].
Several large single-center, open-label, randomized,
controlled studies have assessed the long-term (≥6 months)
effectiveness of lactulose therapy, compared with placebo,
probiotics and/or no therapy. Compared with no treat-
ment or placebo, the calculated NNT values [95% con-
fidence intervals (CIs)] for lactulose as secondary
prophylaxis for OHE recurrence were 3.28 (2.15–6.90)
[34] and 3.68 (2.33–8.75) [38] (Fig. 2).
In a primary prophylaxis study, patients with cirrhosis
but no previous history of OHE were randomized to
receive lactulose therapy (n=60) or no lactulose therapy
(n= 60) for 12 months [39]. Lactulose significantly
reduced the rate of OHE occurrence versus no lactulose
(11 vs. 28%; P=0.02) and reduced the median length of
stay for HE-related hospitalization, although not sig-
nificantly [39]. In a secondary prophylaxis study, patients
with cirrhosis who had recovered from OHE were ran-
domized to receive lactulose (n= 68), probiotics (n=64) or
no therapy (n=65) for up to 12 months [34]. The rate of
OHE recurrence was 26.5% with lactulose, 34.4% with
probiotics and 56.9% with no therapy (lactulose vs. pro-
biotics, P=not significant; lactulose vs. no therapy,
P=0.001; and probiotics vs. no therapy, P=0.02) [34].
The mortality rate was 19.1, 17.2 and 24.6% for the
lactulose, probiotics and no therapy groups, respectively
(P= not significant between groups) [34]. In a similar
secondary prophylaxis study, patients were randomized to
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receive lactulose or placebo over a median follow-up
duration of 14 months [38]. Lactulose was significantly
superior to placebo in reducing the rate of OHE recurrence
(19.6 vs. 46.8%; P= 0.001) but not in reducing the rate of
hospitalization for non-HE events or mortality [38].
Rifaximin with or without lactulose
Most rifaximin studies assessed the additional benefit of
rifaximin prophylaxis as an adjunct to lactulose therapy.
Compared with placebo + lactulose, NNT values (95%
CIs) for rifaximin + lactulose as secondary prophylaxis for
OHE recurrence were calculated to be 3.28 (2.27–5.90)
[16] and 4.21 (2.93–7.46) [19] (Fig. 2).
A phase III, multicenter, randomized, double-blind,
placebo-controlled trial compared the effectiveness of
rifaximin-α 550mg twice daily versus placebo for the
prevention of OHE recurrence over 6 months in 299
patients with cirrhosis who had experienced at least two
OHE episodes in the previous 6 months but who were
currently in remission [19]. More than 90% of patients in
both treatment arms additionally received lactulose ther-
apy. The rate of OHE recurrence was 22.1% with rifax-
imin versus 45.9% with placebo [19]. The hazard ratio for
the time to a breakthrough OHE episode for rifaximin
versus placebo was 0.42 (95% CI: 0.28–0.64; P< 0.001),
reflecting a relative risk reduction of 58% with rifaximin
versus placebo [19]. The rate of HE-related hospital
readmission was 13.6% with rifaximin versus 22.6% with
placebo, and the hazard ratio for time to first HE-related
hospitalization for rifaximin versus placebo was 0.50
(95% CI: 0.29–0.87; P=0.01), representing a 50% rela-
tive reduction in risk [19]. In a subanalysis of this trial
(n=219), conducted primarily to assess health-related
quality of life, the rate of OHE recurrence was 25.7%
with rifaximin versus 50.0% with placebo, and HE
remission was maintained for 6 months in 74.3% of
patients treated with rifaximin versus 50.0% of those
treated with placebo [32].
In a similarly designed single-center, randomized, triple-
blind, placebo-controlled trial, 126 patients with cirrhosis
who were admitted to hospital with an index OHE event,
having experienced at least one other OHE event in the
previous 6 months, were treated with rifaximin-α 550mg
or placebo for 6 months, in addition to lactulose therapy
[15]. In this trial, rate of HE recurrence was 44.4% with
rifaximin versus 36.5% with placebo (P= not significant),
and the mortality rate was 11.1% in both treatment
groups [15].
When examining long-term use specifically, patients
completing the trial by Bass and colleagues were eligible to
enter a phase III, multicenter, open-label maintenance
study, in which patients received open-label treatment with
rifaximin-α 550mg for 24 months [18]. In total, 392
patients were treated with rifaximin (‘all-rifaximin’ group),
including 252 patients who received de novo treatment
(‘new-rifaximin’ group). As in the initial trial, ~ 90% of
patients were additionally treated with lactulose. The rates
of HE-related hospitalization were 0.21 and 0.23 events/
person-year of exposure (PYE) for the all-rifaximin and
new-rifaximin groups, respectively [18]. In the original
trial, the corresponding values were 0.30 events/PYE for
rifaximin versus 0.72 events/PYE for placebo (P<0.0001)
[18]. A post-hoc analysis of this study was conducted for
321 patients who had been treated for mean duration of
1.5 years [17]. Data were compared between patients who
had been newly recruited, having not participated in the
original trial (‘rifaximin-newly recruited’ group), with
those who received rifaximin in the original randomized
controlled trial (‘rifaximin-RCT’ group) and those who
received placebo in the original trial (‘placebo-RCT’
group) [17]. The rates of OHE recurrence were 772.1,
687.2 and 652.1 events/1000 person-years for the
rifaximin-newly recruited, rifaximin-RCT and placebo-
RCT groups, respectively (P=not significant between
groups), and the corresponding mortality rates were
170.5, 134.1 and 168.5 events/1000 patient years,
respectively (P= not significant between groups) [17].
Fig. 1. Summary of numbers of journal articles indexed on PubMed, identified using the search terms ‘hepatic encephalopathy+ lactulose’ and ‘hepatic
encephalopathy+ rifaximin’. Searches were conducted of titles and abstracts only, with language restricted to English and the date range unrestricted up to the
cutoff date (5 March 2018). aArticles without an abstract; barticles containing primary clinical trial, clinical practice study, observational, registry, health
economic, or survey data, including journal-published congress abstracts, if indexed on PubMed; c≥ 6 months; darticles relating to rifaximin alone or in
combination with lactulose; earticles relating to lactulose alone.
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Table 1. Articles reporting effectiveness outcomes over the long term (≥6 months) for patients treated with rifaximin and/or lactulose for hepatic encephalopathy. Articles reporting data for rifaximin and
lactulose are presented in the rifaximin section; those reporting data for lactulose, but not rifaximin, are presented in the lactulose section.
Efficacy outcomes
References Study design Rifaximin Tx
Number of
patients Study population Study durationa
Time to first
breakthrough
HE episode
(HR or days)
Time to first
HE-related
hospitalization
(HR)
Patients with
breakthrough HE
episodes (%,
events/PYE, events/
1000 person-years,
number of HE
episodes/patient)
HE-related hospital
readmission
(%, events/PYE,
number of
hospitalizations,
number of bed days,
number of critical
care bed days, LOS)
All-cause hospital
readmission
(%, events/PYE,
number of
hospitalizations,
days of
hospitalization,
weeks of
hospitalization, LOS)
Mortality (%, events/1000
person-years) Other end points
Rifaximin
Ali et al. [15] Single-center, randomized,
triple-blind, placebo-
controlled trial
550 b.i.d 63 (R)
63 (P)
All patients
additionally
received L
Cirrhosis; ≥2 HE
episodes in last
6 months; Conn≥2;
MELD≤25
6 months – – OHE (Conn ≥2):
44.4% (R) vs.
36.5% (P);
P=0.56
– – 11.1% (R) vs. 11.1% (P) –
Bajaj et al. [16] Post-hoc analysis of
multicenter, randomized,
double-blind, placebo-
controlled trial, followed
by multicenter, single-
arm OLM study
Study compared patients
who received R during
OLM having switched
from P at end of RCT
with the same patients
when treated with P
during RCT
550 b.i.d 82 (P during
RCT and R
during OLM)
L use was
permitted:
use was
91.2% (P
during RCT)
and ~90%
(R during
OLM)
Cirrhosis; history of
OHE; Conn≥2
within last 6 months;
Conn≤1 at
enrolment;
MELD≤25
6 months
(RCT) + 24 months
(OLM)
HR (R during
OLM vs. P
during RCT)
0.21
(95% CI
0.10–0.44;
P<0.0001;
RR 79%)
– OHE (Conn ≥2):
17.1% (R during first
6 months of
OLM) vs. 47.6%
(P during RCT);
P<0.0001
0.42 events/PYE (R
during first
6 months of
OLM) vs. 1.50 (P
during RCT);
P<0.0001
0.36 Events/PYE (R
during first
6 months of
OLM) vs. 0.57
events/PYE (P
during RCT);
P=0.365
0.82 Events/PYE (R
during first
6 months of
OLM) vs. 0.80
events/PYE (P
during RCT);
P=NS
– –
Bannister et al. [17] Post-hoc analysis of
multicenter, phase III,
OLM study [18]
550 b.i.d 321 (R):
169 newly
recruited (R-
NR)
70 R during
RCT
(R-RCT)
82 P during
RCT
(P-RCT)
History of ≥1 OHE
episode (Conn≥2)
within 12 months of
screening; Conn≤2
at enrolment
1.5 years – – Events/1000
person-years:
687.2 (R-RCT)
vs. 772.1 (R-NR)
vs. 652.1
(P-RCT); P=NS
between groups
– – Events/1000 person-
years:
134.1 (R-RCT) vs. 170.5
(R-NR)
vs. 168.5 (P-RCT);
P=NS between
groups
–
Bass et al. [19] Multicenter, randomized,
double-blind, placebo-
controlled trial
550 b.i.d 140 (R)
159 (P)
L use was
permitted:
use was
91.4%
(R group)
and 91.2%
(P group)
Cirrhosis; ≥2 OHE
episodes (Conn≥2)
in last 6 months; in
remission (Conn 0 or
1); MELD≤25
6 months HR (R vs. P)
0.42 (95%
CI
0.28–0.64;
P<0.001;
RR 58%)
HR (R vs. p)
0.50 (95%
CI
0.29–0.87;
P=0.01;
RR 50%)
OHE (increase from
Conn 0 or 1 at
baseline to Conn
≥2, or increase
from Conn 0 at
baseline to Conn
1+a 1-unit
increase in
asterixis grade):
22.1% (R) vs.
45.9% (P)
13.6% (R) vs.
22.6% (P)
– – –
Courson et al. [20] Single-center,
retrospective, cohort
study
550 b.i.d 62 (R+L)
87 (L)
Admitted for HE 180 days – – – 2.4% (L+R) vs.
16.2% (L);
P=0.028
52.4% (L+R) vs.
41.2% (L);
P=0.252
Median LOS: 8 days
(L+R) vs. 6 days
(L); P=0.09
32% (L+R) vs. 22% (L);
P=0.15
–
Goyal et al. [21] Single-center, randomized,
prospective study
400 t.i.d 57 (R)
55 (L)
Cirrhosis; MHE 3 months Tx +
6 months FU
(results relate to
9-month FU)
– – MHE: 47.6% (R) vs.
42.1% (L);
P=0.274
OHE: 7.1% (R) vs.
7.9% (L);
P=0.924
– – 0.23% (R) vs. 0% (L);
P=NS
–
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)
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Riggio et al. [36] Single-center,
randomized,
controlled study
Initial 30 ml/day
(in 2 divided
doses)
15 (L)
16 (La)
Cirrhosis; surgical portal-
systemic anastomosis
6 months – – 40% (L) vs. 28.6%
(La); P=NS
– – – –
Riggio et al. [37] Single-center,
randomized,
crossover study
38.2 ±19 g/day
(range
30–78 g/day)
12 (L/La) Cirrhosis; surgical
nonselective portosystemic
shunt
2×6 months Tx (mean
FU: 57 ± 49 months)
– – 60% (L) vs. 25%
(La); P=0.21
– – – –
Sharma et al.
[38]
Single-center, open-
label, randomized,
controlled trial
30–60 ml/day
(in 2/3 divided
doses)
70 (L)
70 (P)
Cirrhosis; recovered from HE Median FU: 14 months
(range: 1–20 months)
– – OHE (West-Haven
≥2):
19.6% (L) vs. 46.8% (P);
P=0.001
– 14.7% (L) vs. 9.3% (P);
P=NS (Note:
hospitalizations for non-
HE events rather than all-
cause)
8% (L) vs. 17%
(P); P=0.18
–
Sharma et al.
[39]
Single-center, open-
label, randomized,
controlled trial
30–60 ml/day
(in 2/3 divided
doses)
60 (L)
60 (no L)
Cirrhosis; no previous OHE 12 months – – OHE (West-Haven
≥2):
11% (L) vs. 28% (no L);
P=0.02
Median (range)
LOS for HE:
6 (4–16) (L) vs. 7
(3–20) (no L);
P=0.07
18% (L) vs. 14% (no L)
(P= value not specified)
(Note: hospitalizations
for non-HE events rather
than all-cause)
9% (L) vs. 20%
(no L); P=0.16
–
Takuma et al.
[40]
Single-center,
prospective,
randomized,
controlled study
30–60 ml/day 39 (ZS)
40 (no ZS)
All patients
received L
Cirrhosis; hyperammonaemia;
grade 1 or 2 recurrent
episodic HE unresponsive to
standard therapies (lactulose
and protein-restricted diet) for
≥4 weeks
6 months – – Average number of HE
episodes/patient at
baseline and 6 months:
3.8±1.2 and 1.8±1.8
(ZS) vs. 3.7±1.2 and
3.6±2.3 (no ZS),
respectively; P<0.05
for ZS vs. no ZS;
P<0.05 for ZS
baseline vs. ZS
6 months
– – – Average HE grade at
baseline and 6 months:
1.4±0.5 and 0.9±0.9
(ZS) vs. 1.4±0.5 and
1.3±0.9 (no ZS),
respectively; P<0.05
for ZS vs. no ZS;
P<0.05 for ZS
baseline vs. ZS
6 months
b.i.d, twice daily; C, control; CI, confidence interval; CLD, chronic liver disease; FU, follow-up; HCC, hepatocellular carcinoma; HE, hepatic encephalopathy; Hist-P, historical placebo; Hist-R, historical rifaximin; HR, hazard ratio; HRQOL,
health-related quality of life; HS, hepatorenal syndrome; ICD, International Classification of Diseases; L, lactulose; La, lactitol; LOS, length of stay; MELD, model for end-stage liver disease; MHE, minimal hepatic encephalopathy; N,
neomycin; NR, not reported; NT, no therapy; o.d., once-daily; OHE, overt hepatic encephalopathy; OLM, open-label maintenance; OR, odds ratio; P, placebo; PB, probiotics; P-RCT, placebo during randomized controlled trial; PYE, person-
years of exposure; R, rifaximin; RCT, randomized controlled trial; RD, rifaximin daily; RI, rifaximin intermittent (14 days/month); R-NR, rifaximin-newly recruited; RR, relative reduction; R-RCT, rifaximin during randomized controlled trial; S,
statistically significant; SBP, spontaneous bacterial peritonitis; t.i.d, three times daily; Tx, treatment; ZS, zinc supplementation.
aOnly time points ≥6 months are shown.
bPer patient.
cTotal number.
dAll patients who received rifaximin (i.e. those who received rifaximin in RCT, those who received rifaximin or placebo in RCT and continued into OLM, and those who were newly enrolled in OLM).
ePatients who received placebo in RCT and switched to rifaximin in OLM+ those newly enroled in OLM.
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In addition to these prospective data, several large ret-
rospective studies have assessed the effectiveness of
rifaximin + lactulose in comparison with lactulose alone.
The IMPRESS study was a multicenter, retrospective,
observational study of 207 patients with HE, 84% of
whom received concomitant lactulose, designed to assess
the effect of rifaximin-α 550mg on hospital resource use
[22]. Outcomes were compared for the 6 months before
starting rifaximin (‘pre-rifaximin’) versus the 6 months
following rifaximin initiation (‘post-rifaximin’), and for
12 months pre-rifaximin versus 12 months post-rifaximin.
OHE episodes were experienced by 57% of patients in the
12 months pre-rifaximin versus 38% in the 12 months
post-rifaximin [22]. The mean number of HE episodes per
patient decreased significantly from the 12 months pre-
rifaximin to the 12 months post-rifaximin (P=0.047) [22].
A single-center, retrospective, cohort study compared
the effectiveness of rifaximin (600mg, twice daily) +
lactulose versus lactulose alone in patients with cirrhosis-
related HE who either did or did not have hepatocellular
carcinoma (HCC) [24]. Median follow-up was 18.0 months
in the non-HCC population (n=421) and 4.4 months in the
HCC population (n=621) [24]. In the non-HCC popula-
tion, the rate of HE recurrence was 15.9% for rifaximin-
+ lactulose versus 33.3% for lactulose alone (P<0.001),
and the overall mortality rate was 36.6% for rifaximin-
+ lactulose versus 56.9% for lactulose alone (P=0.02) [24].
Furthermore, NNT analysis showed that 9.6 patients
without HCC would need to be treated with rifaximin to
increase the survival rate of one patient each year [24]. In
the HCC population, the rate of HE recurrence was
19.1% for rifaximin + lactulose versus 29.2% for lactu-
lose alone (P= 0.03), and the overall mortality rate was
75.1% for rifaximin + lactulose versus 82.8% for lactu-
lose alone (P= not significant) [24]. In both the non-HCC
and HCC populations, rates of spontaneous bacterial
peritonitis and variceal bleeding were significantly lower
for rifaximin + lactulose versus lactulose alone [24].
Finally, a single-center, retrospective, cohort study of patients
admitted for HE compared the effectiveness of rifaximin-α
550mg+ lactulose (n=62) versus lactulose alone (n=87)
over 180 days [20]. The rate of HE-related hospital read-
mission was significantly lower with rifaximin + lactulose
versus lactulose alone (2.4 vs. 16.2%; P= 0.028), but
the rate of all-cause hospital readmission was not sig-
nificantly different between groups, and neither were
the median length of hospital stay or the rate of
mortality [20].
Studies have also assessed the effectiveness of different
rifaximin treatment regimens when used in addition to
lactulose therapy. No significant differences were observed
between patients treated with rifaximin-α 550mg once-
daily versus twice daily [25], or between patients treated
with rifaximin-α 550mg twice daily versus rifaximin
400mg, three times daily; although rifaximin-α 550mg
twice daily was shown to be more cost-effective than the
three times daily regimen [27].
Direct head-to-head evidence of the long-term effec-
tiveness of rifaximin versus lactulose is scarce. In a single-
center, retrospective chart review, 145 patients diagnosed
with HE received at least 6 months of treatment with
lactulose before receiving at least 6 months of treatment
with rifaximin (400mg, three times daily), and outcomes
were compared for the last 6 months of lactulose treatment
versus the first 6 months of rifaximin treatment [26]. The
number of hospitalizations per patient was significantly
lower with rifaximin versus lactulose (0.5 vs. 1.6;
P< 0.001), as was the number of days of hospitalization
per patient (2.5 vs. 7.3; P<0.001) and number of weeks of
hospitalization per patient (0.4 vs. 1.8; P< 0.001) [26].
Rifaximin was also compared with lactulose in a single-
center, prospective study, designed to investigate for how
long patients with MHE should be treated [21]. Patients
with cirrhosis with MHE were randomized to receive
primary prophylaxis treatment with either rifaximin
(400mg, three times daily) or lactulose for 3 months, and
Fig. 2. NNTs with 95% CIs for lactulose versus no lactulose/placebo [34,38], rifaximin+ lactulose versus placebo+ lactulose [16,19], and rifaximin mono-
therapy versus rifaximin+ lactulose [31]. CI, confidence interval; NNT, number needed to treat.
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Table 2. Articles reporting safety/tolerability outcomes over the long term (≥6 months) for patients treated with rifaximin and/or lactulose for hepatic encephalopathy. Articles reporting data for rifaximin and
lactulose are presented in the rifaximin section; those reporting data for lactulose, but not rifaximin, are presented in the lactulose section
Safety outcomes
References Study design Rifaximin Tx
Number of
patients Study population Study durationa
Incidence of
AEs (%, rate/
PYE until AE)
Type of AEs (%,
rate/PYE until AE) Serious AEs (%)
Infection-related
AEs (rate/PYE
until AE)
Death (%,
deaths/PYE)
Discontinuation
due to AEs (%)
Other safety
results
Rifaximin
Ali et al. [15] Single-center,
randomized, triple-
blind, placebo-
controlled trial
550 b.i.d 63 (R)
63 (P)
All patients
additionally
received L
Cirrhosis; ≥ 2 HE
episodes in
last 6 months;
Conn ≥2;
MELD≤ 25
6 months – Abdominal pain:
1.6% (R) vs. 0%
(P)
Nausea and
vomiting: 4.8%
(R) vs. 3.2% (P)
Sore throat/fatigue:
0% (R) vs. 1.6%
(P)
General weakness:
1.6% (R) vs. 0%
(P)
– – 11.1% (R) vs.
11.1% (P)
– –
Bajaj et al.
[16]
Post-hoc analysis of
multicenter,
randomized, double-
blind, placebo-
controlled trial,
followed by single-
arm OLM study
Study compared
patients who
received R during
OLM having switched
from P at end of RCT
with the same
patients when treated
with P during RCT
550 b.i.d 82 (P during
RCT and R
during OLM)
L use was
permitted:
use was
91.2% (P
during RCT)
and ~90%
(R during
OLM)
Cirrhosis; history
of OHE; Conn
≥ 2 within last
6 months;
Conn≤1 at
enrolment;
MELD≤ 25
6 months
(RCT)+24 months
(OLM)
– Rate/PYE until AE
(R during OLM
vs. P during
RCT)a:
Ascites: 0.27 vs.
0.19
Headache: 0.0 vs.
0.38
Nausea: 0.26 vs.
0.47
Peripheral oedema:
0.29 vs. 0.36
R during OLMb anaemia (3.7%),
ascites (3.7%), cellulitis (3.7%),
hyponatraemia (3.7%), acute renal
failure (2.4%), chest pain (2.4%),
hepatic cirrhosis (2.4%),
hypoglycaemia (2.4%),
hyperkalaemia (2.4%), pneumonia
(2.4%), UTI (2.4%)
P during RCTb: Atrial fibrillation
(2.4%), bacterial peritonitis (2.4%),
cellulitis (2.4%)
Rate/PYE until
AE (R during
OLM vs. P
during RCT)b:
Cellulitis: 0.17 vs.
0.08
Peritonitis: 0.06
vs. 0.11
Pneumonia: 0.08
vs. 0.0
Sepsis/septic
shock: 0.08
vs. 0.08
UTI/kidney
infection: 0.14
vs. 0.29
– – Change from
baseline in PT:
0.42 s (R
during OLM)
vs. -0.04 s (P
during RCT)
Change from
baseline in
INR: −0.01
(R during
OLM) vs.
−0.04 (P
during RCT)
No clinically
significant
changes in
laboratory
values from
baseline to
Month 6 for R
during OLM
Bass et al.
[19]
Multicenter, randomized,
double-blind,
placebo-controlled
trial
550 b.i.d 140 (R)
159 (P)
L use was
permitted:
use was
91.4%
(R group)
and 91.2%
(P group)
Cirrhosis; ≥ 2
OHE episodes
(Conn ≥ 2) in
last 6 months;
in remission
(Conn 0 or 1);
MELD≤ 25
6 months 80.0% (R)
vs. 79.9%
(P)
AEsa:
Nausea: 14.3% (R)
vs. 13.2% (P)
Diarrhoea: 10.7%
(R) vs. 13.2% (P)
Fatigue: 12.1% (R)
vs. 11.3% (P)
Peripheral oedema:
15.0% (R) vs.
8.2% (P)
Ascites: 11.4% (R)
vs. 9.4% (P)
Dizziness: 12.9%
(R) vs. 8.2% (P)
Headache: 10.0%
(R) vs. 10.7% (P)
Note: P> 0.05 for
all comparisons
Serious AEsc:
Anaemia: 2.9% (R) vs. 0% (P)
Ascites: 2.9% (R) vs. 2.5% (P)
Oesophageal varices: 2.9% (R)
vs. 1.3% (P)
Pneumonia: 2.9% (R) vs. 0.6% (P)
Vomiting: 2.1% (R) vs. 0% (P)
Generalized oedema: 2.1% (R)
vs. 1.3% (P)
Hepatic cirrhosis: 2.1% (R)
vs. 3.8% (P)
Cellulitis: 2.1% (R) vs. 1.3% (P)
Acute renal failure: 1.4% (R)
vs. 2.5% (P)
Note: P>0.05 for all comparisons
AEs possibly
related to
infectionb:
Bacterial
peritonitis:
1.4% (R) vs.
2.5% (P)
Pneumonia:
2.9% (R) vs.
0.6% (P)
GI haemorrhage:
0.7% (R) vs.
1.9% (P)
Haematochezia:
1.4% (R) vs.
0.6% (P)
Bacteraemia:
0.7% (R) vs.
1.3% (P)
Gastritis: 1.4%
(R) vs. 0% (P)
C. difficile
infection: 1.4%
(R) vs. 0% (P)
Sepsis: 0% (R) vs.
1.3% (P)
Note: P>0.05 for
all comparisons
6.4% (R) vs.
6.9% (P)
– –
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Table 2. (Continued)
Safety outcomes
References Study design Rifaximin Tx
Number of
patients Study population Study durationa
Incidence of
AEs (%, rate/
PYE until AE)
Type of AEs (%,
rate/PYE until AE) Serious AEs (%)
Infection-related
AEs (rate/PYE
until AE)
Death (%,
deaths/PYE)
Discontinuation
due to AEs (%)
Other safety
results
Hudson et al.
[22]
Multicenter,
retrospective,
observational study
1100 mg/day
(34%)
1200mg/day
(61%)
Other doses (5%)
207 (R)
84% of patients
received
concomitant
L
Documented
clinical
diagnosis of
HE; initiated on
R ≥ 12 months
before data
collection
12 months 4.3% (R) AEs:
C. difficile infection:
1.9% (R)
Rash: 1.0% (R)
Abdominal pain:
0.5% (R)
Teeth discoloration:
0.5% (R)
None C. difficile
infection:
1.9% (R)
19%
(6 months
post-R);
27%
(12 months
post-R)
None –
Kang et al.
[24]
Single-center,
retrospective cohort
study
600 b.i.d 318 (R+L)
724 (L)
Cirrhosis-related
HE; recovered
after medical
treatment
Median (IQR) follow-
up:
18.0 (4.3–36.3)
months (non-HCC)
4.4 (1.3–16.4) months
(HCC)
– – – C. difficile-
associated
diarrhoea:
0.3% (R+L)
vs. 1.0% (L);
P=NS
– – –
Leevy and
Phillips
[26]
Single-center,
retrospective, chart
review
400 t.i.d 145 (R)
145 (L)
All patients
received L
and then
switched to
R
HE diagnosis 6 months
(last 6 months on L
was compared with
first 6 months on R)
– Diarrhoea*
Mild: 93% (R) vs.
8% (L)
Moderate: 6% (R)
vs. 59% (L)
Severe: <1% (R) vs.
22% (L)
Very severe: 0% (R)
vs. 10% (L)
Flatulence*
Mild: 97% (R) vs.
26% (L)
Moderate: 3% (R)
vs. 54% (L)
Severe: 0% (R) vs.
11% (L)
Very severe: 0% (R)
vs. 9% (L)
Abdominal pain*
Mild: 86% (R) vs.
38% (L)
Moderate: 11% (R)
vs. 46% (L)
Severe: 2% (R) vs.
10% (L)
Very severe: <1%
(R) vs. 6% (L)
Headache
Mild: 86% (R) vs.
82% (L)
Moderate: 10% (R)
vs. 12% (L)
Severe: 3% (R) vs.
5% (L)
Very severe: 0% (R)
vs. <1% (L)
*P<0.001, R vs. L
– – – – % Patients with
grade 3 or 4
HE: 6% (R)
vs. 25% (L);
P< 0.001
(for overall
difference in
HE grade)
% patients with
asterixis:
63% (R) vs.
93% (L);
P< 0.001
Mantry and
Munsaf
[28]
Single-center,
retrospective chart
review
400–1200mg/day 65
All received L
followed by
R alone (16)
or with L (49)
Study
compared L
(i.e. L alone
pre-R) with R
(R/R+L)
Treated for HE 6 months 2% (R) vs.
86% (L);
P<0.001
Abdominal pain: 2%
(R) vs. 29% (L)
Excessive
diarrhoea: 0%
(R) vs. 83% (L)
Cramping: 0% (R)
vs. 32% (L)
Bloating: 0% (R) vs.
12% (L)
Severe dehydration: 0% (R) vs. 1.5%
(L)
– – 2% (R) vs. 37%
(L);
P<0.001
% Patients with
SBP: 2% (R)
vs. 12% (L);
P= 0.02
444
E
uro
p
ean
Jo
urnalo
f
G
astro
entero
lo
g
y
&
H
ep
ato
lo
g
y
A
pril2019
•
Volum
e
31
•
N
um
ber
4
Mullen et al.
[18]
Multicenter, phase III,
OLM study
550 b.i.d 392 (all-R)d
252 (new-R)e
In all-R (N= 392):
352 (R+ L)
40 (R alone)
In original RCT:
140 (Hist-R)
159 (Hist-P)
History of OHE
(Conn ≥ 2) within
12 months of
screening;
Conn≤ 2 at
screening;
patients from
previous RCT
24 months Rate/PYE
until AE:
0.71 (all-R)
vs. 0.69
(new-R) vs.
2.24 (Hist-R)
vs. 2.76
(Hist-P)
Rate/PYE until AE:
Complications of
portal hypertension
All AEs: 0.57 (all-R) vs.
0.96 (Hist-R) vs.
0.89 (Hist-P)
Acute kidney injury/
HS: 0.15 (all-R) vs.
0.04 (Hist-R) vs.
0.20 (Hist-P)
Ascites and oedema:
0.39 (all-R) vs. 0.81
(Hist-R) vs. 0.69
(Hist-P)
Varices and variceal/
GI bleed: 0.12 (all-
R) vs. 0.12 (Hist-R)
vs. 0.15 (Hist-P)
Haematological
complications
All AEs: 0.18 (all-R) vs.
0.27 (Hist-R) vs.
0.16 (Hist-P)
Anaemia: 0.14 (all-R)
vs. 0.23 (Hist-R) vs.
0.13 (Hist-P)
Thrombocytopenia/
coagulation: 0.07
(all-R) vs. 0.06
(Hist-R) vs. 0.02
(Hist-P)
Other
Electrolyte imbalance:
0.11 (all-R) vs. 0.12
(Hist-R) vs. 0.07
(Hist-P)
Fatigue/sleep
disorders: 0.2 (all-
R) vs. 0.58 (Hist-R)
vs. 0.70 (Hist-P)
Muscular atrophy: 0.02
(all-R) vs. 0 (Hist-R)
vs. 0.04 (Hist-P)
Rate/PYE until AE: 0.48 (all-R) vs.
0.46 (new-R) vs. 1.02 (Hist-R) vs. 1.37
(Hist-P)
Rate/PYE until
AE:
All infections: 0.73
(all-R) vs. 1.12
(Hist-R) vs. 1.33
(Hist-P)
Cellulitis: 0.07 (all-
R) vs. 0.06 (Hist-
R) vs. 0.07 (Hist-
P)
C. difficile infection:
0.01 (all-R) vs.
0.04 (Hist-R) vs.
0 (Hist-P)
Peritonitis: 0.04 (all-
R) vs. 0.06 (Hist-
R) vs. 0.13 (Hist-
P)
Pneumonia: 0.08
(all-R) vs. 0.08
(Hist-R) vs. 0.02
(Hist-P)
Sepsis/septic
shock: 0.06 (all-
R) vs. 0.04 (Hist-
R) vs. 0.11 (Hist-
P)
UTI/kidney
infection: 0.19
(all-R) vs. 0.19
(Hist-R) vs. 0.32
(Hist-P)
19.4% (All-R);
no deaths
attributed to R
Deaths/PYE:
0.15 (all-R) vs.
0.24 (Hist-P)
Rate/PYE until
AE: 0.25 (all-R)
vs. 0.22 (new-R)
vs. 0.60 (Hist-R)
vs. 0.98 (Hist-P)
GI AEs in all-R
population
based on
lactulose use
(Rate/PYE until
AE):
All AEs: 0.51 (R)
vs. 1.19 (R+ L)
Abdominal pain:
0.09 (R) vs.
0.20 (R+L)
Ascites: 0.09 (R)
vs. 0.15 (R+ L)
GI bleeding event:
0.08 (R) vs.
0.14 (R+L)
Nausea: 0.05 (R)
vs. 0.23 (R+ L)
Constipation: 0.06
(R) vs. 0.11
(R+ L)
Vomiting: 0.04 (R)
vs. 0.13 (R+ L)
Diarrhoea: 0.04 (R)
vs. 0.12 (R+ L)
Oesophageal
varices: 0.04
(R) vs. 0.05
(R+ L)
Diverticulum: 0.04
(R) vs. 0.01
(R+ L)
Abdominal
distension: 0.02
(R) vs. 0.05
(R+ L)
Neff et al.
[41]
Multicenter,
retrospective chart
review
Mean (range) 1055
(600–1600) mg/
day
211 (R)
All patients
additionally
received
lactulose
Cirrhosis; treated
with R for HE
Mean (range) 250
(180–385) days
– Diarrhoea: 8%
No patients had
C. difficile infection
– – – – –
Lactulose
Agrawal
et al. [34]
Single-center, open-
label, randomized,
controlled trial
30–60 ml/day (in
2/3 divided doses)
68 (L)
64 (PB)
65 (NT)
Cirrhosis;
previous history of
HE; no OHE
Up to 12 months – L: diarrhoea
(26.4%), abdominal
bloating (16.2%),
distaste to L
(17.6%)
PB: constipation
(21.8%), abdominal
distension (14%)
NT: constipation
(21.5%)
– – – – –
Lactulo
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Table 2. (Continued)
Safety outcomes
References Study design Rifaximin Tx
Number of
patients Study population Study durationa
Incidence of
AEs (%, rate/
PYE until AE)
Type of AEs (%,
rate/PYE until AE) Serious AEs (%)
Infection-related
AEs (rate/PYE
until AE)
Death (%,
deaths/PYE)
Discontinuation
due to AEs (%)
Other safety
results
Moratalla
et al. [35]
Two-center, prospective,
observational study
30–60ml/day First cohort:
26 (L)
46 (no L)
Second cohort:
40 (L)
MHE 6 months – First cohort: no AEs
Second cohort:
L: transient
diarrhoea
(12.5%),
flatulence (7.5%)
– – – – –
Riggio et al.
[36]
Single-center,
randomized,
controlled study
Initial 30 ml/day (in
2 divided doses)
15 (L)
16 (La)
Cirrhosis; surgical
portal-systemic
anastomosis
6 months – L: meteorism
(40%), flatulence
(40%), nausea
(6.7%)
La: nausea (6.3%),
asthenia (6.3%),
epigastric pain
(6.3%; treatment
stopped)
– – – – –
Riggio et al.
[37]
Single-center,
randomized,
crossover study
38.2 ± 19 g/day
(range 30–78 g/
day)
12 (L/La) Cirrhosis; surgical
non-selective
portosystemic
shunt
2×6 months Tx
(mean FU
57 ± 49 months)
– L: meteorism
(58.3%),
flatulence
(58.3%)
La: flatulence
(16.7%), nausea
(8.3%)
– – – – –
Sharma et al.
[38]
Single-center, open-
label, randomized,
controlled trial
30–60ml/day (in
2/3 divided
doses)
70 (L)
70 (P)
Cirrhosis;
recovered from
HE
Median FU 14 months
(range
1–20 months)
– L: diarrhoea (23%),
abdominal
bloating (10%),
distaste to L
(13%)
P: constipation
(16%)
– – – – –
Sharma et al.
[39]
Single-center, open-
label, randomized,
controlled trial
30–60ml/day (in
2/3 divided
doses)
60 (L)
60 (no L)
Cirrhosis; no
previous OHE
12 months – L: diarrhoea (24%),
distaste to L
(20%),
abdominal
bloating (8%)
– – – – –
AE, adverse event; b.i.d, twice daily; C, control; FU, follow-up; GI, gastrointestinal; HE, hepatic encephalopathy; Hist-P, historical placebo; Hist-R, historical rifaximin; HS, hepatorenal syndrome; INR, international normalized ratio; L,
lactulose; La, lactitol; MELD, Model for End-stage Liver Disease; MHE, minimal hepatic encephalopathy; NT, no therapy; OHE, overt hepatic encephalopathy; OLM, open-label maintenance; P, placebo; PB, probiotics; PYE, person-years of
exposure; R, rifaximin; RCT, randomized controlled trial; SBP, spontaneous bacterial peritonitis; t.i.d, three times daily; Tx, treatment; UTI, urinary tract infection.
aReported in ≥10% patients.
bReported in ≥2 patients.
cReported in ≥2% patients.
dAll patients who received rifaximin (i.e. those who received rifaximin in RCT, those who received rifaximin or placebo in RCT and continued into OLM, and those who were newly enrolled in OLM).
ePatients who received placebo in RCT and switched to rifaximin in OLM+ those newly enroled in OLM.
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then followed up for a further 6 months [21]. After
9 months, the rate of MHE recurrence was 47.6% for
rifaximin versus 42.1% for lactulose (P=not significant),
and the rate of OHE occurrence was 7.1% for rifaximin
versus 7.9% with lactulose (P= not significant) [21].
Only one long-term study has assessed the effectiveness
of rifaximin monotherapy with that of rifaximin +
lactulose therapy [31]. Compared with rifaximin +
lactulose, the calculated NNT value (95% CI) for rifax-
imin monotherapy as secondary prophylaxis for OHE
recurrence was 6.88 (3.50–203.90) (Fig. 2). This was a
multicenter, retrospective, chart review comparing 1-year
outcomes of 149 patients with cirrhosis treated with
rifaximin (400–1600mg/day) with those of 54 patients
treated with rifaximin + lactulose [31]. The rate of main-
tenance of HE remission for 1 year was 81% with rifax-
imin monotherapy versus 67% with rifaximin + lactulose
[31]. Mean time to a breakthrough OHE event was
210 days with rifaximin monotherapy versus 90 days with
rifaximin + lactulose [31]. HE-related hospitalization
rates were similar with rifaximin (43%) and rifaximin +
lactulose (39%) [31]. In both groups, response to rifaximin
appeared to be enhanced in patients with a mean baseline
model for end-stage liver disease score of less than or equal
to 20 [31]. These findings appear to contrast with those of
a single-center, retrospective, observational study of 225
patients evaluated for liver transplantation, all of whom
were treated with rifaximin-α 550mg+ lactulose for
6 months, which showed a lower rate of HE-related hos-
pitalization in patients with a model for end-stage liver
disease score of at least 20 versus less than 20 (1.6 vs. 2.5
per 6 months) [29].
Safety/tolerability of long-term (>_ 6 months) treatment of
hepatic encephalopathy with rifaximin and/or lactulose
Manual assessment of the articles containing primary
clinical data identified six articles reporting long-term
safety/tolerability outcomes for treatment with lactulose
alone and a further nine articles reporting long-term safety/
tolerability outcomes for treatment of HE with rifaximin,
alone or in combination with lactulose (Table 2). Details of
studies including more than 100 patients are summarized
in more detail later.
Lactulose alone
Three large single-center, open-label, randomized, con-
trolled studies have assessed the long-term (≥6 months)
safety/tolerability of lactulose therapy, compared with
placebo, probiotics and/or no therapy [34,38,39]. In a
primary prophylaxis study, in which patients with cir-
rhosis but no previous history of OHE were randomized to
receive lactulose therapy (n=60) or no lactulose therapy
(n=60) for 12 months, all patients treated with lactulose
remained adherent to treatment [39]. The most commonly
reported adverse events (AEs) with lactulose were diar-
rhea, distaste to lactulose and abdominal bloating, which
improved following reduction of lactulose dosing [39]. In a
secondary prophylaxis study, in which patients with cir-
rhosis who had recovered from OHE were randomized to
receive lactulose (n=68), probiotics (n=64) or no therapy
(n=65) for up to 12 months, all lactulose patients
remained adherent to treatment [34]. AEs in the lactulose
group again comprised diarrhea, distaste to lactulose and
abdominal bloating [34]. Lactulose dosing was reduced in
these patients but not stopped. In the probiotics group,
AEs comprised constipation and abdominal distension,
which were managed with dietary advice and on-and-off
use of proton pump inhibitors [34]. In the no therapy
group, only constipation was reported, which was mana-
ged with dietary modifications [34]. Similar results were
observed in another secondary prophylaxis study, in which
patients were randomized to receive lactulose or placebo
over a median follow-up duration of 14 months [38]. All
patients remained adherent to lactulose therapy, and AEs
in the lactulose group comprised diarrhea, distaste to lac-
tulose and abdominal bloating [38]. Lactulose dosing was
decreased in these patients but not stopped. In the placebo
group, the only AE was constipation, which was managed
with dietary modifications [38].
Rifaximin with or without lactulose
In the phase III, multicenter, randomized, double-blind,
placebo-controlled trial, carried out by Bass et al. [19],
which compared rifaximin-α 550mg (n= 140) versus
placebo (n=159) for the prevention of OHE recurrence
over 6 months (concomitant lactulose use >90% in both
groups), the overall incidence of AEs was 80.0% with
rifaximin versus 79.9% with placebo. The most commonly
reported AEs (≥10% of patients in either group) were
nausea, diarrhea, fatigue, peripheral edema, ascites, dizzi-
ness and headache, but there were no significant differ-
ences between treatment groups [19]. There were also no
significant differences between groups in the incidences of
serious AEs and AEs related to infection, including
Clostridium difficile infection [19]. Deaths occurred in 6.4
and 6.9% of rifaximin-treated and placebo-treated
patients, respectively [19].
In the similarly designed single-center, randomized,
triple-blind, placebo-controlled trial carried out by Ali
et al. [15], the incidence of AEs was low and similar in
patients treated with rifaximin-α 550mg (n= 63) or pla-
cebo (n= 63) for 6 months, in addition to lactulose ther-
apy. Deaths occurred in 11.1% of patients in both
treatment groups [15].
In the 24-month, open-label maintenance study that
followed the trial by Bass and colleagues, a total 392
patients were treated with rifaximin-α 550mg (‘all-rifax-
imin’ group), including 252 patients who received de novo
treatment (82 patients who received placebo in the original
trial and 170 newly recruited patients; ‘new-rifaximin’
group) [18]. Approximately 90% of the patients in the all-
rifaximin group additionally received treatment with lac-
tulose. Safety/tolerability results were compared with those
for patients who received rifaximin and placebo in the
original phase III trial [‘historical-rifaximin’ (n=140) and
‘historical-placebo’ (n= 159) groups, respectively]. The
overall rates of AEs/PYE were lower in the all-rifaximin
(0.71) and new-rifaximin (0.69) groups than in the
historical-rifaximin (2.24) and historical-placebo (2.76)
groups [18], as were the rates of serious AEs/PYE and
discontinuation owing to AEs (rate/PTE) [18]. The rate of
death/PYE was 0.15 in the all-rifaximin group compared
with 0.24 in the historical-placebo group [18]. The rate of
C. difficile infection remained stable with long-term
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rifaximin treatment [18]. When comparing patients who
received rifaximin in combination with lactulose (n=352)
with those who received rifaximin alone (n= 40), the
incidence of gastrointestinal-related AEs was significantly
higher in the combination therapy group than in the
monotherapy group (69.6 vs. 47.5%; P< 0.001), including
the incidences of nausea and abdominal pain [18].
In the multicenter, retrospective, observational IMPRESS
study of 207 patients with HE (all of whom were treated
with rifaximin-α 550mg and 84% of whom received con-
comitant lactulose), 4.3% of patients had documented AEs,
most commonly C. difficile infection (n=4) and rash (n=2)
[22]. No serious AEs were reported. Of the four patients
who developed C. difficile infection, none had a history of
C. difficile and none was on concomitant antibiotics. All
patients continued rifaximin therapy [22]. In a single-center,
retrospective, cohort study that compared the effectiveness
of rifaximin (600mg, twice daily) + lactulose (n=318) ver-
sus lactulose alone (n=724) in patients with cirrhosis-
related HE who either did or did not have HCC, C. difficile
infection rates were 0.3% with rifaximin+ lactulose versus
1.0% with lactulose alone, over a median follow-up dura-
tion of 18.0 months in patients without HCC and
4.4 months in patients with HCC [24]. In a multicenter,
retrospective chart review of 211 patients treated with
rifaximin (mean: 1055mg/day; range: 600–1600mg/day),
in addition to lactulose, over a mean follow-up duration of
250 days, 8% of patients experienced diarrhea but none
experienced C. difficile infection [41]. All cases of diarrhea
were resolved with standard antidiarrheal therapy, which
was administered after stool analysis excluded C. difficile
infection [41].
Direct head-to-head evidence of the long-term safety/
tolerability of rifaximin versus lactulose is limited to a
single-center, retrospective chart review, in which 145
patients diagnosed with HE received at least 6 months of
treatment with lactulose before receiving at least 6 months
of treatment with rifaximin (400mg, three times daily)
[26]. Outcomes were compared for the last 6 months of
lactulose treatment versus the first 6 months of rifaximin
treatment [26]. The percentages of patients with diarrhea,
flatulence and abdominal pain were significantly higher
during the lactulose period than the rifaximin period
(P<0.001 for all) [26]. There was no significant difference
in the percentage of patients with headache, which was the
only other AE reported [26].
Discussion
This systematic review shows an increasing body of evi-
dence for the use of rifaximin in addition to lactulose, and
for lactulose therapy alone, in the long-term management
of patients with HE. In line with the current guidelines [1],
this evidence supports the use of lactulose therapy as sec-
ondary prophylaxis for the prevention of recurrence of
OHE events over the long term [34,35,38]. In addition,
one study has showed the effectiveness of lactulose as
primary prophylaxis in the prevention of long-term OHE
occurrence [39]. Although there is very little direct head-
to-head evidence of rifaximin versus lactulose over the
long term, there is considerable evidence to support
recommendations for the use of rifaximin as an add-on
treatment to standard lactulose therapy in the secondary
prophylaxis setting [1].
In terms of effectiveness, several long-term, open-label
clinical trials and clinical practice studies have showed
that, when added to lactulose therapy, rifaximin sig-
nificantly reduces the recurrence of OHE events and rate of
HE-related hospitalization, in comparison with lactulose
therapy alone [16,19,20,22,24,28]. An exception to this
was a single-center, randomized, placebo-controlled trial,
carried out by Ali et al., in which rifaximin was found to
be no better than placebo when combined with lactulose
therapy as secondary prophylaxis against OHE recurrence
[15]. In discussing the potential reasons for the discrepancy
in the findings of this trial, compared with those of the
phase III trial by Bass et al. [19], the authors point out that
the study populations differed in terms of primary etiology
of cirrhosis, geographical and dietary background [15].
The authors therefore speculated that the gut flora [42–44]
of the two study populations might have differed.
Nevertheless, the majority of current evidence supports an
enhanced therapeutic benefit in adding rifaximin to lac-
tulose therapy for the prevention of OHE recurrence and
HE-related hospitalization.
Historically, the NNT measure was designed to quan-
tify treatment benefit directly in terms of the number of
patients who would need to be treated before benefit is
observed, thereby providing a means of expressing abso-
lute, as opposed to relative, risk in a clinically meaningful
way [45–47]. Although the number of studies eligible for
inclusion in the current NNT analyses was limited, the
results showed that, in terms of long-term secondary
prophylaxis for the prevention of OHE recurrence,
approximately four patients would need to be treated with
lactulose before clinical benefit is observed, compared with
no treatment or placebo. This must be considered within
the clinical context showing a very high rate of OHE
recurrence with no prophylaxis or with poor adherence to
lactulose therapy. Importantly, to show the add-on benefit
of rifaximin to lactulose, the NNT is approximately four
patients to prevent the recurrence of OHE. The relatively
low NNT value for adding rifaximin to lactulose therapy
provides further support for the clinical benefit of these
treatments for the prevention of OHE recurrence over the
long term. Only one study compared rifaximin mono-
therapy versus rifaximin + lactulose, and NNT analysis
showed that approximately seven patients would need to
be treated with rifaximin monotherapy before clinical
benefit is observed (in comparison with rifaximin +
lactulose). However, the results of this single study should
be viewed with caution, not only because the 95% CI was
very wide but also because the study design was such that
patients who received rifaximin monotherapy may have
had less severe HE than those who received combination
therapy, which may have affected their likelihood of long-
term remission [31].
For chronic conditions such as HE, the success of
treatment is dependent on its tolerability, as patients will
only adhere to treatment if they are able to tolerate it over
the long term. Long-term tolerability problems, such as
adverse gastrointestinal symptoms, also have a major
effect on health-related quality of life [48]. In the case of
lactulose, tolerability is a major clinical consideration. In a
study of 137 patients who received long-term secondary
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prophylaxis with lactulose, 75% experienced OHE recur-
rence, and this was associated with lactulose nonadherence
in 38% of these patients, mainly because of gastro-
intestinal adverse effects, such as unpredictable diarrhea,
abdominal pain and bloating [10]. Crucially, all patients
who were nonadherent on lactulose therapy, and nearly
two-thirds of those who were adherent, experienced OHE
recurrence [10]. There is evidence to suggest that patient
acceptance of lactulose is influenced by sociocultural fac-
tors; for example, in a recent survey of 100 outpatients
with cirrhosis from India and the USA, who did not have
previous or current experience with lactulose but who
underwent dedicated education about its use for HE pre-
vention, a significantly higher proportion of Indian versus
US patients agreed to accept lactulose treatment [49]. In
this context, it is perhaps noteworthy that a substantial
number of the lactulose studies identified in this review
were carried out in patients from the Indian subcontinent.
Taken together, such findings highlight the need for
additional, effective and better tolerated therapeutic
options in the long-term management of HE, across all
sociocultural patient groups.
In the 6-month phase III trial that compared rifaximin-α
550mg with placebo for the prevention of OHE recur-
rence in patients in HE remission, more than 90% of
whom were additionally treated with lactulose, the overall
incidence of AEs was the same in both groups, and there
were no significant between-group differences in the inci-
dence of the most commonly reported AEs and serious AEs
[19]. In the 24-month open-label maintenance study that
followed this trial, the incidences of total AEs, serious AEs
and AEs leading to discontinuation were lower than those
observed in the rifaximin and placebo arms of the original
6-month trial [18]. In addition, long-term retrospective
studies have showed a low incidence of AEs when rifax-
imin is added to lactulose therapy in clinical practice [22,
41]. As with nearly all antibacterial agents, C. difficile-
associated diarrhea has been reported with rifaximin
treatment [13]. However, this has not emerged as a major
safety concern following long-term treatment in clinical
trials [18,19] and in clinical practice studies [22,24,41].
HE is associated with a substantial economic burden,
primarily because of the direct costs of hospitalization and
rehospitalization following recurrence, and secondarily
because of the indirect costs associated with outpatient
care, disability, lost productivity and the wider negative
effect on the lives of patients’ caregivers [1,50,51]. As
previously discussed, current evidence for the long-term
treatment of HE with rifaximin as an add-on to lactulose
therapy demonstrates that it not only significantly
decreases OHE recurrence, in comparison with lactulose
therapy alone, but also significantly reduces the rate of
HE-associated hospitalization and length of hospital stay
[16,19,20,22,24,28,52]. There is therefore a substantial
body of evidence showing that the addition of rifaximin to
standard lactulose therapy results in significant reductions
in healthcare resource utilization over the long term.
A limitation of this systematic review was that, fol-
lowing a thorough assessment of the available data, meta-
analysis of outcome measures was found to be unfeasible
and inappropriate, because of the heterogeneity of the
designs, treatment settings and patient populations of the
studies that were identified. NNT analysis was also limited
by the low number of studies that could be assessed in
this way.
Conclusion
Current evidence supports recommendations for the use of
lactulose therapy for the prevention of OHE recurrence
over the long term, and for the additional benefit of adding
rifaximin to lactulose therapy. The addition of rifaximin to
lactulose significantly further reduces the risk of OHE
recurrence and HE-related hospitalization, compared with
lactulose therapy alone, with a demonstrably low NNT to
achieve these further benefits. There is also emerging evi-
dence to indicate that a switch to rifaximin monotherapy
may be appropriate for those for whom lactulose is inef-
fective and/or poorly tolerated, and/or when adherence to
lactulose therapy is problematic, although this requires
further research.
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